Florbetapir-PET findings could help fuel drug development, researchers say

03/12/2014 | AuntMinnie.com (free registration)

Positive scans with florbetapir-PET were associated with faster cognitive declines over three years than negative scans in a new study. The findings, which appear in Molecular Psychiatry, support previous data and could assist with the development of new treatments. "If we can accurately identify individuals who are likely to progress compared to individuals who are not likely to progress, that can help drug discovery, even though we don't have a treatment right now to prevent Alzheimer's," said lead author Dr. P. Murali Doraiswamy.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA